<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> (FA) is an <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> condition associated with congenital abnormalities, progressive <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, and a predisposition to <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We studied a retrospective cohort of North American patients with FA </plain></SENT>
<SENT sid="2" pm="."><plain>We calculated relative risks of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> compared to the general population and cause-specific hazards of the first major adverse outcomes of FA: bone marrow transplantation (BMT) for marrow complications, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, or <z:hpo ids='HP_0011420'>death</z:hpo> from <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We also estimated the cumulative incidence of each adverse event in the presence of the competing risks </plain></SENT>
<SENT sid="4" pm="."><plain>Among 145 patients with FA, 9 developed <z:hpo ids='HP_0001909'>leukemia</z:hpo> and 14 developed a total of 18 solid <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The ratio of observed to expected <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (O/E ratio) was 50 for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, 48 for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, and 785 for <z:hpo ids='HP_0001909'>leukemia</z:hpo>; these increased risks were statistically significant </plain></SENT>
<SENT sid="6" pm="."><plain>The highest <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> O/E ratios were 4317 for <z:e sem="disease" ids="C0677055" disease_type="Neoplastic Process" abbrv="">vulvar cancer</z:e>, 2362 for <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, and 706 for <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Cause-specific hazards of both <z:hpo ids='HP_0011420'>death</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> peaked at 1%/y in teenage years; the hazard of BMT peaked at 4%/y at age 7 </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, the hazard of a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> approached 8%/y by age 40 years </plain></SENT>
<SENT sid="9" pm="."><plain>The cumulative incidence to age 48 was 10% for <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 11% for <z:hpo ids='HP_0011420'>death</z:hpo> from marrow failure, 29% for a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e>, and 43% for BMT </plain></SENT>
<SENT sid="10" pm="."><plain>The risk of a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> may become even higher as <z:hpo ids='HP_0011420'>death</z:hpo> from <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> is reduced and as patients survive longer after BMT </plain></SENT>
</text></document>